{ "responseHeader":{ "status":0, "QTime":0, "params":{ "q":"iati_identifier:GB-GOV-10-PDP_GARDP_NS", "fl":"*", "format":"json" } }, "response":{ "numFound":1, "start":0, "numFoundExact":true, "docs":[{ "default-currency":"GBP", "default_currency":"GBP", "hierarchy":1, "humanitarian":false, "last-updated-datetime":"2026-03-25T11:12:22.540Z", "last_updated_datetime":"Wed Mar 25 11:12:22 UTC 2026", "last_updated_datetime_f":"2026-03-25T11:12:22.540Z", "lang":"en", "default_lang":"en", "iati-identifier":"GB-GOV-10-PDP_GARDP_NS", "iati_identifier":"GB-GOV-10-PDP_GARDP_NS", "reporting-org.ref":"GB-GOV-10", "reporting_org_ref":"GB-GOV-10", "reporting-org.type":"10", "reporting_org_type_code":"10", "reporting-org.narrative":["UK - Department of Health and Social Care (DHSC)"], "reporting_org_narrative":["UK - Department of Health and Social Care (DHSC)"], "reporting-org.narrative.lang":[" "], "title.narrative":["Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support"], "title_narrative":["Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support"], "title_narrative_text":["Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support"], "title.narrative.lang":[" "], "title_narrative_lang":[" "], "description.type":["1","2"], "description_type":["1","2"], "description.narrative":["A partnership to fund the development of new treatments for severe bacterial infections in neonates under GARDP’s Neonatal Sepsis Programme","The overall purpose of GARDP’s neonatal sepsis programme is to develop up to three new or improved treatments for newborns with severe bacterial infections by 2023. The activities funded under this programme will make an important contribution towards achieving these objectives by prioritising three work packages with the following focus:\n1. Improve clinical management of neonatal sepsis\nThis work package includes three key activities: completion of the global observational study; commencing clinical programme to develop a treatment to be used in place of the current WHO recommended empiric treatment, ampicillin and gentamicin for neonatal sepsis, and conducting clinical and laboratory capability strengthening in support of the clinical programme.\n2. Developing new and improved treatments for multi drug-resistant infections in neonates\nThis work package will aim to develop an effective and safe treatment for confirmed or highly suspected MDR-GN pathogens, including K. pneumoniae, or Acinetobacter spp., that is affordable and adapted for use in neonates.\n3. Accelerating regulatory approval and access in high burden LMICs\nThrough this work package, GARDP will work with WHO, pharmaceutical companies and regulatory authorities to ensure the newly developed treatments are globally accessible and that they are not ‘lost’ to resistance within a few years after their introduction. To achieve this, GARDP, in partnership with the relevant partner(s), will develop regulatory, public health and market access (including supply and distribution) strategies for any treatments developed."], "description_narrative":["A partnership to fund the development of new treatments for severe bacterial infections in neonates under GARDP’s Neonatal Sepsis Programme","The overall purpose of GARDP’s neonatal sepsis programme is to develop up to three new or improved treatments for newborns with severe bacterial infections by 2023. The activities funded under this programme will make an important contribution towards achieving these objectives by prioritising three work packages with the following focus:\n1. Improve clinical management of neonatal sepsis\nThis work package includes three key activities: completion of the global observational study; commencing clinical programme to develop a treatment to be used in place of the current WHO recommended empiric treatment, ampicillin and gentamicin for neonatal sepsis, and conducting clinical and laboratory capability strengthening in support of the clinical programme.\n2. Developing new and improved treatments for multi drug-resistant infections in neonates\nThis work package will aim to develop an effective and safe treatment for confirmed or highly suspected MDR-GN pathogens, including K. pneumoniae, or Acinetobacter spp., that is affordable and adapted for use in neonates.\n3. Accelerating regulatory approval and access in high burden LMICs\nThrough this work package, GARDP will work with WHO, pharmaceutical companies and regulatory authorities to ensure the newly developed treatments are globally accessible and that they are not ‘lost’ to resistance within a few years after their introduction. To achieve this, GARDP, in partnership with the relevant partner(s), will develop regulatory, public health and market access (including supply and distribution) strategies for any treatments developed."], "description_narrative_text":["A partnership to fund the development of new treatments for severe bacterial infections in neonates under GARDP’s Neonatal Sepsis Programme","The overall purpose of GARDP’s neonatal sepsis programme is to develop up to three new or improved treatments for newborns with severe bacterial infections by 2023. The activities funded under this programme will make an important contribution towards achieving these objectives by prioritising three work packages with the following focus:\n1. Improve clinical management of neonatal sepsis\nThis work package includes three key activities: completion of the global observational study; commencing clinical programme to develop a treatment to be used in place of the current WHO recommended empiric treatment, ampicillin and gentamicin for neonatal sepsis, and conducting clinical and laboratory capability strengthening in support of the clinical programme.\n2. Developing new and improved treatments for multi drug-resistant infections in neonates\nThis work package will aim to develop an effective and safe treatment for confirmed or highly suspected MDR-GN pathogens, including K. pneumoniae, or Acinetobacter spp., that is affordable and adapted for use in neonates.\n3. Accelerating regulatory approval and access in high burden LMICs\nThrough this work package, GARDP will work with WHO, pharmaceutical companies and regulatory authorities to ensure the newly developed treatments are globally accessible and that they are not ‘lost’ to resistance within a few years after their introduction. To achieve this, GARDP, in partnership with the relevant partner(s), will develop regulatory, public health and market access (including supply and distribution) strategies for any treatments developed."], "description.narrative.lang":[" "," "], "description_narrative_lang":[" "," "], "participating-org.ref":["GB-GOV-10","GB-GOV-10","GB-GOV-10","CH-FDJP-CHE331930936"], "participating_org_ref":["GB-GOV-10","GB-GOV-10","GB-GOV-10","CH-FDJP-CHE331930936"], "participating-org.role":["1","2","3","4"], "participating_org_role":["1","2","3","4"], "participating-org.type":["10","10","10","30"], "participating_org_type":["10","10","10","30"], "participating-org.narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","Global Antibiotic Research and Development Partnership"], "participating_org_narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","Global Antibiotic Research and Development Partnership"], "participating_org_narrative_text":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","Global Antibiotic Research and Development Partnership"], "participating-org.narrative.lang":[" "," "," "," "], "participating_org_narrative_lang":[" "," "," "," "], "activity-status.code":"4", "activity_status_code":"4", "activity-date.iso-date":["2020-03-01T00:00:00Z","2020-03-01T00:00:00Z","2021-03-31T00:00:00Z","2021-03-31T00:00:00Z"], "activity_date_iso_date":["2020-03-01T00:00:00Z","2020-03-01T00:00:00Z","2021-03-31T00:00:00Z","2021-03-31T00:00:00Z"], "activity-date.type":["1","2","3","4"], "activity_date_type":["1","2","3","4"], "contact-info.type":["1"], "contact_info_type":["1"], "contact-info.organisation.narrative":["UK - Department of Health and Social Care (DHSC)"], "contact_info_organisation_narrative":["UK - Department of Health and Social Care (DHSC)"], "contact_info_organisation_narrative_text":["UK - Department of Health and Social Care (DHSC)"], "contact-info.organisation.narrative.lang":[" "], "contact_info_organisation_narrative_lang":[" "], "contact-info.department.narrative":["Science, Research and Evidence"], "contact_info_department_narrative":["Science, Research and Evidence"], "contact_info_department_narrative_text":["Science, Research and Evidence"], "contact-info.department.narrative.lang":[" "], "contact_info_department_narrative_lang":[" "], "contact-info.person-name.narrative":["Global Health Research Programme"], "contact_info_person_name_narrative":["Global Health Research Programme"], "contact_info_person_name_narrative_text":["Global Health Research Programme"], "contact-info.person-name.narrative.lang":[" "], "contact_info_person_name_narrative_lang":[" "], "contact-info.email":["GlobalHealthResearch@dhsc.gov.uk"], "contact_info_email":["GlobalHealthResearch@dhsc.gov.uk"], "contact-info.website":["https://www.nihr.ac.uk/funding-and-support/global-health-research/"], "contact_info_website":["https://www.nihr.ac.uk/funding-and-support/global-health-research/"], "contact-info.mailing-address.narrative":["7th Floor South Wing, 39 Victoria Street, London, SW1H 0EU"], "contact_info_mailing_address_narrative":["7th Floor South Wing, 39 Victoria Street, London, SW1H 0EU"], "contact_info_mailing_address_narrative_text":["7th Floor South Wing, 39 Victoria Street, London, SW1H 0EU"], "contact-info.mailing-address.narrative.lang":[" "], "contact_info_mailing_address_narrative_lang":[" "], "activity-scope.code":"1", "activity_scope_code":"1", "recipient-region.code":["998"], "recipient_region_code":["998"], "recipient-region.vocabulary":["1"], "recipient_region_vocabulary":["1"], "sector.code":["12182"], "sector_code":["12182"], "sector.percentage":[100.0], "sector_percentage":[100.0], "sector.vocabulary":["1"], "sector_vocabulary":["1"], "sector.narrative":["Medical research"], "sector_narrative":["Medical research"], "sector_narrative_text":["Medical research"], "sector.narrative.lang":[" "], "sector_narrative_lang":[" "], "tag.code":["RI"], "tag_code":["RI"], "tag.vocabulary":["99"], "tag_vocabulary":["99"], "tag.vocabulary-uri":["https://devtracker.fcdo.gov.uk/custom-codes"], "tag_vocabulary_uri":["https://devtracker.fcdo.gov.uk/custom-codes"], "tag.narrative":["Research and Innovation"], "tag_narrative":["Research and Innovation"], "tag_narrative_text":["Research and Innovation"], "tag.narrative.lang":[" "], "tag_narrative_lang":[" "], "collaboration-type.code":"1", "collaboration_type_code":"1", "default-flow-type.code":"10", "default_flow_type_code":"10", "default-finance-type.code":"110", "default_finance_type_code":"110", "default-aid-type.code":["C01"], "default_aid_type":["C01"], "default_aid_type_category_code":["C01"], "default_aid_type_code":["C01"], "default-tied-status.code":"5", "default_tied_status_code":"5", "budget.status":["1","1"], "budget_status":["1","1"], "budget.type":["1","1"], "budget_type":["1","1"], "budget.period-start.iso-date":["2019-04-01T00:00:00Z","2020-04-01T00:00:00Z"], "budget_period_start_iso_date":["2019-04-01T00:00:00Z","2020-04-01T00:00:00Z"], "budget.period-end.iso-date":["2020-03-31T00:00:00Z","2021-03-31T00:00:00Z"], "budget_period_end_iso_date":["2020-03-31T00:00:00Z","2021-03-31T00:00:00Z"], "budget.value":[2164656.0,1835344.0], "budget_value":[2164656.0,1835344.0], "budget.value.currency":["GBP","GBP"], "budget_value_currency":["GBP","GBP"], "budget.value.value-date":["2020-03-01T00:00:00Z","2020-03-01T00:00:00Z"], "budget_value_date":["2020-03-01T00:00:00Z","2020-03-01T00:00:00Z"], "capital-spend.percentage":100.0, "capital_spend_percentage":100.0, "transaction.transaction-type.code":["2","3","3","3"], "transaction_type":["2","3","3","3"], "transaction.transaction-date.iso-date":["2019-12-05T00:00:00Z","2019-12-13T00:00:00Z","2020-06-26T00:00:00Z","2020-11-27T00:00:00Z"], "transaction_date_iso_date":["2019-12-05T00:00:00Z","2019-12-13T00:00:00Z","2020-06-26T00:00:00Z","2020-11-27T00:00:00Z"], "transaction.value":[4000000.0,2164656.0,783474.0,1051870.0], "transaction_value":[4000000.0,2164656.0,783474.0,1051870.0], "transaction.description.narrative":["GB-GOV-10-PDP_GARDP_NS COMMITMENT","GB-GOV-10-PDP_GARDP_NS 2019/20 Q3 DISBURSEMENT","GB-GOV-10-PDP_GARDP_NS 2020/21 Q1 DISBURSEMENT","GB-GOV-10-PDP_GARDP_NS 2020/21 Q3 DISBURSEMENT"], "transaction_description_narrative":["GB-GOV-10-PDP_GARDP_NS COMMITMENT","GB-GOV-10-PDP_GARDP_NS 2019/20 Q3 DISBURSEMENT","GB-GOV-10-PDP_GARDP_NS 2020/21 Q1 DISBURSEMENT","GB-GOV-10-PDP_GARDP_NS 2020/21 Q3 DISBURSEMENT"], "transaction.description.narrative.lang":[" "," "," "," "], "transaction_description_lang":[" "," "," "," "], "transaction.provider-org.provider-activity-id":["GB-GOV-10-PDP_GARDP_NS","GB-GOV-10-PDP_GARDP_NS","GB-GOV-10-PDP_GARDP_NS","GB-GOV-10-PDP_GARDP_NS"], "transaction_provider_org_provider_activity_id":["GB-GOV-10-PDP_GARDP_NS","GB-GOV-10-PDP_GARDP_NS","GB-GOV-10-PDP_GARDP_NS","GB-GOV-10-PDP_GARDP_NS"], "transaction.provider-org.ref":["GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10"], "transaction_provider_org_ref":["GB-GOV-10","GB-GOV-10","GB-GOV-10","GB-GOV-10"], "transaction.provider-org.narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)"], "transaction_provider_org_narrative":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)"], "transaction_provider_org_narrative_text":["UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)","UK - Department of Health and Social Care (DHSC)"], "transaction.provider-org.narrative.lang":[" "," "," "," "], "transaction_provider_org_narrative_lang":[" "," "," "," "], "transaction.receiver-org.ref":["CH-FDJP-CHE331930936","CH-FDJP-CHE331930936","CH-FDJP-CHE331930936","CH-FDJP-CHE331930936"], "transaction_receiver_org_ref":["CH-FDJP-CHE331930936","CH-FDJP-CHE331930936","CH-FDJP-CHE331930936","CH-FDJP-CHE331930936"], "transaction.receiver-org.narrative":["Global Antibiotic Research and Development Partnership","Global Antibiotic Research and Development Partnership","Global Antibiotic Research and Development Partnership","Global Antibiotic Research and Development Partnership"], "transaction_receiver_org_narrative":["Global Antibiotic Research and Development Partnership","Global Antibiotic Research and Development Partnership","Global Antibiotic Research and Development Partnership","Global Antibiotic Research and Development Partnership"], "transaction_receiver_org_narrative_text":["Global Antibiotic Research and Development Partnership","Global Antibiotic Research and Development Partnership","Global Antibiotic Research and Development Partnership","Global Antibiotic Research and Development Partnership"], "transaction.receiver-org.narrative.lang":[" "," "," "," "], "transaction_receiver_org_narrative_lang":[" "," "," "," "], "transaction.value.currency":["GBP","GBP","GBP","GBP"], "transaction_value_currency":["GBP","GBP","GBP","GBP"], "transaction.value.value-date":["2019-12-05T00:00:00Z","2019-12-13T00:00:00Z","2020-06-26T00:00:00Z","2020-11-27T00:00:00Z"], "transaction_value_date":["2019-12-05T00:00:00Z","2019-12-13T00:00:00Z","2020-06-26T00:00:00Z","2020-11-27T00:00:00Z"], "conditions.attached":false, "conditions_attached":"0", "reporting-org.type.name":"Government", "reporting_org_type_name":"Government", "recipient-region.name":["Developing countries, unspecified"], "recipient_region_name":["Developing countries, unspecified"], "default-aid-type.name":["Project-type interventions"], "default_aid_type_category_name":["Project-type interventions"], "budget.type.name":["Original","Original"], "budget.status.name":["Indicative","Indicative"], "tag.vocabulary.name":["Reporting Organisation"], "title.narrative.first":"Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support", "title_narrative_first":"Global Antibiotic Research and Development Partnership’s Neonatal Sepsis Programme (GARDP) support", "activity-date.start-planned":"2020-03-01T00:00:00Z", "activity_date_start_planned":"Sun Mar 01 00:00:00 UTC 2020", "activity_date_start_planned_f":"2020-03-01T00:00:00Z", "activity-date.common.start":"2020-03-01T00:00:00Z", "activity_date_start_common":"Sun Mar 01 00:00:00 UTC 2020", "activity_date_start_common_f":"2020-03-01T00:00:00Z", "activity-date.start-actual":"2020-03-01T00:00:00Z", "activity_date_start_actual":"Sun Mar 01 00:00:00 UTC 2020", "activity_date_start_actual_f":"2020-03-01T00:00:00Z", "activity-date.end-planned":"2021-03-31T00:00:00Z", "activity_date_end_planned":"Wed Mar 31 00:00:00 UTC 2021", "activity_date_end_planned_f":"2021-03-31T00:00:00Z", "activity-date.common.end":"2021-03-31T00:00:00Z", "activity_date_end_common":"Wed Mar 31 00:00:00 UTC 2021", "activity_date_end_common_f":"2021-03-31T00:00:00Z", "activity-date.end-actual":"2021-03-31T00:00:00Z", "activity_date_end_actual":"Wed Mar 31 00:00:00 UTC 2021", "activity_date_end_actual_f":"2021-03-31T00:00:00Z", "activity-status.text":"Closed", "activity_status_text":"Closed", "budget.value-usd":[2678869.3483409653,2271329.3868686296], "budget_value_usd":[2678869.3483409653,2271329.3868686296], "budget.value-usd.sum":4950198.735209595, "budget_value_usd_sum":4950198.735209595, "budget.value-usd.conversion-rate":[0.808048366129009,0.808048366129009], "budget_usd_conversion_rate":[0.808048366129009,0.808048366129009], "budget.value-usd.conversion-currency":["GBP"], "budget.value-gbp":[2164656.0,1835344.0], "budget_value_gbp":[2164656.0,1835344.0], "budget.value-gbp.sum":4000000.0, "budget_value_gbp_sum":4000000.0, "budget.value-gbp.conversion-rate":[1.0,1.0], "budget_gbp_conversion_rate":[1.0,1.0], "budget.value-gbp.conversion-currency":["GBP"], "transaction.value-usd.sum":1.0463800227684245E7, "transaction_value_usd_sum":1.0463800227684245E7, "transaction.value-usd.conversion-rate":[0.7616165040410569,0.7616165040410569,0.7986112621319575,0.7575141228962491], "transaction_usd_conversion_rate":[0.7616165040410569,0.7616165040410569,0.7986112621319575,0.7575141228962491], "transaction.value-usd.conversion-currency":["GBP"], "transaction.value-gbp.sum":8000000.0, "transaction_value_gbp_sum":8000000.0, "transaction.value-gbp.conversion-rate":[1.0,1.0,1.0,1.0], "transaction_gbp_conversion_rate":[1.0,1.0,1.0,1.0], "transaction.value-gbp.conversion-currency":["GBP"], "dataset.id":"bce0347a-c08e-4d93-86ce-c44d7adc5c93", "dataset_iati_id":"bce0347a-c08e-4d93-86ce-c44d7adc5c93", "dataset.name":"dhsc-activities-ghr", "dataset_name":"dhsc-activities-ghr", "dataset.extras.iati_version":"2.03", "dataset.resources.hash":"5a2fa4a2f378e3034bb8e88e541b337f92b20e0f", "dataset.resources.url":"https://dhsc-govuk.github.io/iati-oda-spending-metadata/dhsc-activities-ghr.xml", "activity-date.quarter":[1,1,1,1], "budget.period-start.quarter":[2,2], "budget.period-end.quarter":[1,1], "transaction.transaction-date.quarter":[4,4,2,4], "transaction.value-usd":[5251987.0286114095,2842186.308351465,981045.5188278371,1388581.371893533], "transaction_value_usd":[5251987.0286114095,2842186.308351465,981045.5188278371,1388581.371893533], "transaction.value-usd-type":[2,3,3,3], "transaction.value-gbp":[4000000.0,2164656.0,783474.0,1051870.0], "transaction_value_gbp":[4000000.0,2164656.0,783474.0,1051870.0], "transaction.value-gbp-type":[2,3,3,3], "activity-aggregation.budget.value":4000000.0, "activity_aggregation_budget_value":4000000.0, "activity-aggregation.budget.value-usd":4950198.735209595, "activity_aggregation_budget_value_usd":4950198.735209595, "activity-aggregation.budget.value-gbp":4000000.0, "activity_aggregation_budget_value_gbp":4000000.0, "activity-aggregation.budget.currency":"GBP", "activity_aggregation_budget_currency":"GBP", "activity-aggregation.outgoing-commitment.value":4000000.0, "activity_aggregation_commitment_value":4000000.0, "activity-aggregation.outgoing-commitment.value-usd":5251987.0286114095, "activity_aggregation_commitment_value_usd":5251987.0286114095, "activity-aggregation.outgoing-commitment.value-gbp":4000000.0, "activity_aggregation_commitment_value_gbp":4000000.0, "activity-aggregation.disbursement.value":4000000.0, "activity_aggregation_disbursement_value":4000000.0, "activity-aggregation.disbursement.value-usd":5211813.199072835, "activity_aggregation_disbursement_value_usd":5211813.199072835, "activity-aggregation.disbursement.value-gbp":4000000.0, "activity_aggregation_disbursement_value_gbp":4000000.0, "json.reporting-org":"{\"ref\": \"GB-GOV-10\", \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}", "json.title":"{\"narrative\": \"Global Antibiotic Research and Development Partnership\\u2019s Neonatal Sepsis Programme (GARDP) support\", \"narrative.lang\": \" \"}", "json.description":["{\"type\": 1, \"narrative\": \"A partnership to fund the development of new treatments for severe bacterial infections in neonates under GARDP\\u2019s Neonatal Sepsis Programme\", \"narrative.lang\": \" \"}","{\"type\": 2, \"narrative\": \"The overall purpose of GARDP\\u2019s neonatal sepsis programme is to develop up to three new or improved treatments for newborns with severe bacterial infections by 2023. The activities funded under this programme will make an important contribution towards achieving these objectives by prioritising three work packages with the following focus:\\n1. Improve clinical management of neonatal sepsis\\nThis work package includes three key activities: completion of the global observational study; commencing clinical programme to develop a treatment to be used in place of the current WHO recommended empiric treatment, ampicillin and gentamicin for neonatal sepsis, and conducting clinical and laboratory capability strengthening in support of the clinical programme.\\n2. Developing new and improved treatments for multi drug-resistant infections in neonates\\nThis work package will aim to develop an effective and safe treatment for confirmed or highly suspected MDR-GN pathogens, including K. pneumoniae, or Acinetobacter spp., that is affordable and adapted for use in neonates.\\n3. Accelerating regulatory approval and access in high burden LMICs\\nThrough this work package, GARDP will work with WHO, pharmaceutical companies and regulatory authorities to ensure the newly developed treatments are globally accessible and that they are not \\u2018lost\\u2019 to resistance within a few years after their introduction. To achieve this, GARDP, in partnership with the relevant partner(s), will develop regulatory, public health and market access (including supply and distribution) strategies for any treatments developed.\", \"narrative.lang\": \" \"}"], "json.participating-org":["{\"ref\": \"GB-GOV-10\", \"role\": 1, \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}","{\"ref\": \"GB-GOV-10\", \"role\": 2, \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}","{\"ref\": \"GB-GOV-10\", \"role\": 3, \"type\": 10, \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}","{\"ref\": \"CH-FDJP-CHE331930936\", \"role\": 4, \"type\": 30, \"narrative\": \"Global Antibiotic Research and Development Partnership\", \"narrative.lang\": \" \"}"], "json.activity-date":["{\"iso-date\": \"2020-03-01\", \"type\": 1}","{\"iso-date\": \"2020-03-01\", \"type\": 2}","{\"iso-date\": \"2021-03-31\", \"type\": 3}","{\"iso-date\": \"2021-03-31\", \"type\": 4}"], "json.contact-info":["{\"type\": 1, \"organisation\": {\"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"department\": {\"narrative\": \"Science, Research and Evidence\", \"narrative.lang\": \" \"}, \"person-name\": {\"narrative\": \"Global Health Research Programme\", \"narrative.lang\": \" \"}, \"email\": \"GlobalHealthResearch@dhsc.gov.uk\", \"website\": \"https://www.nihr.ac.uk/funding-and-support/global-health-research/\", \"mailing-address\": {\"narrative\": \"7th Floor South Wing, 39 Victoria Street, London, SW1H 0EU\", \"narrative.lang\": \" \"}}"], "json.recipient-region":["{\"code\": 998, \"vocabulary\": 1}"], "json.sector":["{\"code\": 12182, \"percentage\": 100, \"vocabulary\": 1, \"narrative\": \"Medical research\", \"narrative.lang\": \" \"}"], "json.tag":["{\"code\": \"RI\", \"vocabulary\": 99, \"vocabulary-uri\": \"https://devtracker.fcdo.gov.uk/custom-codes\", \"narrative\": \"Research and Innovation\", \"narrative.lang\": \" \"}"], "json.default-aid-type":["{\"code\": \"C01\"}"], "json.budget":["{\"status\": 1, \"type\": 1, \"period-start\": [{\"iso-date\": \"2019-04-01\"}], \"period-end\": [{\"iso-date\": \"2020-03-31\"}], \"value\": 2164656, \"value.currency\": \"GBP\", \"value.value-date\": \"2020-03-01\"}","{\"status\": 1, \"type\": 1, \"period-start\": [{\"iso-date\": \"2020-04-01\"}], \"period-end\": [{\"iso-date\": \"2021-03-31\"}], \"value\": 1835344, \"value.currency\": \"GBP\", \"value.value-date\": \"2020-03-01\"}"], "json.transaction":["{\"transaction-type\": {\"code\": 2}, \"transaction-date\": {\"iso-date\": \"2019-12-05\"}, \"value\": 4000000, \"description\": {\"narrative\": \"GB-GOV-10-PDP_GARDP_NS COMMITMENT\", \"narrative.lang\": \" \"}, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-PDP_GARDP_NS\", \"ref\": \"GB-GOV-10\", \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"CH-FDJP-CHE331930936\", \"narrative\": \"Global Antibiotic Research and Development Partnership\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2019-12-05\"}","{\"transaction-type\": {\"code\": 3}, \"transaction-date\": {\"iso-date\": \"2019-12-13\"}, \"value\": 2164656, \"description\": {\"narrative\": \"GB-GOV-10-PDP_GARDP_NS 2019/20 Q3 DISBURSEMENT\", \"narrative.lang\": \" \"}, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-PDP_GARDP_NS\", \"ref\": \"GB-GOV-10\", \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"CH-FDJP-CHE331930936\", \"narrative\": \"Global Antibiotic Research and Development Partnership\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2019-12-13\"}","{\"transaction-type\": {\"code\": 3}, \"transaction-date\": {\"iso-date\": \"2020-06-26\"}, \"value\": 783474, \"description\": {\"narrative\": \"GB-GOV-10-PDP_GARDP_NS 2020/21 Q1 DISBURSEMENT\", \"narrative.lang\": \" \"}, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-PDP_GARDP_NS\", \"ref\": \"GB-GOV-10\", \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"CH-FDJP-CHE331930936\", \"narrative\": \"Global Antibiotic Research and Development Partnership\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2020-06-26\"}","{\"transaction-type\": {\"code\": 3}, \"transaction-date\": {\"iso-date\": \"2020-11-27\"}, \"value\": 1051870, \"description\": {\"narrative\": \"GB-GOV-10-PDP_GARDP_NS 2020/21 Q3 DISBURSEMENT\", \"narrative.lang\": \" \"}, \"provider-org\": {\"provider-activity-id\": \"GB-GOV-10-PDP_GARDP_NS\", \"ref\": \"GB-GOV-10\", \"narrative\": \"UK - Department of Health and Social Care (DHSC)\", \"narrative.lang\": \" \"}, \"receiver-org\": {\"ref\": \"CH-FDJP-CHE331930936\", \"narrative\": \"Global Antibiotic Research and Development Partnership\", \"narrative.lang\": \" \"}, \"value.currency\": \"GBP\", \"value.value-date\": \"2020-11-27\"}"], "json.conditions":"{\"attached\": 0}", "id":"35ee6772-2aab-4583-9044-6469785ee730", "_version_":1865393007366242304 }] } }